Compile Data Set for Download or QSAR
Report error Found 56 of ic50 data for polymerid = 6707
TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141416(US8921364, 67 | US10668051, Compound Example 67)
Affinity DataIC50: 20.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141426(US8921364, 84 | US10668051, Compound Example 84)
Affinity DataIC50: 20.8nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141438(US8921364, 104 | US10668051, Compound Example 104)
Affinity DataIC50: 23.0nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141428(US8921364, 87 | US10668051, Compound Example 87)
Affinity DataIC50: 32.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141421(US8921364, 78 | US10668051, Compound Example 78)
Affinity DataIC50: 34.1nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141424(US8921364, 82 | US10668051, Compound Example 82)
Affinity DataIC50: 35.7nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141396(US8921364, 7 | US10668051, Compound Example 7)
Affinity DataIC50: 36.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141444(US8921364, 114 | US10668051, Compound Example 114)
Affinity DataIC50: 37.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141442(US8921364, 111 | US10668051, Compound Example 111)
Affinity DataIC50: 47.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141419(US8921364, 74 | US10668051, Compound Example 74)
Affinity DataIC50: 48.0nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141425(US8921364, 83 | US10668051, Compound Example 83)
Affinity DataIC50: 48.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141418(US8921364, 72 | US10668051, Compound Example 72)
Affinity DataIC50: 48.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141441(US8921364, 108 | US10668051, Compound Example 108)
Affinity DataIC50: 50.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141448(US8921364, 126 | US10668051, Compound Example 126)
Affinity DataIC50: 52.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141439(US8921364, 106 | US10668051, Compound Example 106)
Affinity DataIC50: 60nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141402(US8921364, 28 | US10668051, Compound Example 28)
Affinity DataIC50: 60.3nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141393(US8921364, 1 | US10668051, Compound Example 1)
Affinity DataIC50: 62.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141443(US8921364, 113 | US10668051, Compound Example 113)
Affinity DataIC50: 62.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141412(US8921364, 56 | US10668051, Compound Example 56)
Affinity DataIC50: 63.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141409(US8921364, 49 | US10668051, Compound Example 49)
Affinity DataIC50: 65.5nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141440(US8921364, 107 | US10668051, Compound Example 107)
Affinity DataIC50: 70.3nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141411(US8921364, 53 | US10668051, Compound Example 53)
Affinity DataIC50: 72.0nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141445(US8921364, 122 | US10668051, Compound Example 122)
Affinity DataIC50: 72.1nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141434(US8921364, 93 | US10668051, Compound Example 93)
Affinity DataIC50: 81.3nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141429(US8921364, 88 | US10668051, Compound Example 88)
Affinity DataIC50: 98.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141436(US8921364, 100 | US10668051, Compound Example 100)
Affinity DataIC50: 99.7nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141414(US8921364, 60 | US10668051, Compound Example 60)
Affinity DataIC50: 120nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141422(US8921364, 79 | US10668051, Compound Example 79)
Affinity DataIC50: 124nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141413(US8921364, 57 | US10668051, Compound Example 57)
Affinity DataIC50: 125nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141399(US8921364, 17 | US10668051, Compound Example 17)
Affinity DataIC50: 130nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141397(US8921364, 15 | US10668051, Compound Example 15)
Affinity DataIC50: 141nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141403(US8921364, 33 | US10668051, Compound Example 33)
Affinity DataIC50: 145nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141427(US8921364, 86 | US10668051, Compound Example 86)
Affinity DataIC50: 147nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141437(US8921364, 101 | US10668051, Compound Example 101)
Affinity DataIC50: 150nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141432(US8921364, 91 | US10668051, Compound Example 91)
Affinity DataIC50: 159nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141433(US8921364, 92 | US10668051, Compound Example 92)
Affinity DataIC50: 159nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141406(US8921364, 37 | US10668051, Compound Example 37)
Affinity DataIC50: 181nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141410(US8921364, 52 | US10668051, Compound Example 52)
Affinity DataIC50: 184nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141404(US8921364, 35 | US10668051, Compound Example 35)
Affinity DataIC50: 185nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141423(US8921364, 80 | US10668051, Compound Example 80)
Affinity DataIC50: 194nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141430(US8921364, 89 | US10668051, Compound Example 89)
Affinity DataIC50: 206nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141394(US8921364, 2 | US10668051, Compound Example 2)
Affinity DataIC50: 207nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141405(US8921364, 36 | US10668051, Compound Example 36)
Affinity DataIC50: 224nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141431(US8921364, 90 | US10668051, Compound Example 90)
Affinity DataIC50: 232nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141398(US8921364, 16 | US10668051, Compound Example 16)
Affinity DataIC50: 244nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141415(US8921364, 66 | US10668051, Compound Example 66)
Affinity DataIC50: 255nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141395(US8921364, 4 | US10668051, Compound Example 4)
Affinity DataIC50: 256nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141420(US8921364, 76 | US10668051, Compound Example 76)
Affinity DataIC50: 269nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141446(US8921364, 124 | US10668051, Compound Example 124)
Affinity DataIC50: 295nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEF-hand calcium-binding domain-containing protein 4B(Human)
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141447(US8921364, 125 | US10668051, Compound Example 125)
Affinity DataIC50: 373nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

Displayed 1 to 50 (of 56 total ) | Next | Last >>
Jump to: